Horizon Discovery and H3 Biomedicine Announce Oncology Collaboration

Horizon Discovery and biopharmaceutical company H3 Biomedicine have announced a new collaboration agreement.

Horizon Discovery and H3 Biomedicine have entered into a collaboration agreement to identify and validate a panel of new cancer drug targets.

Horizon provides research tools to support the development of personalised medicines and its unique gene editing technology and isogenic cell lines will be employed by H3 Biomedicine as it seeks to discover novel oncology treatments.

The two companies will work together to decide whether or not certain targets should be progressed into development.

Any resulting clinical trials will be conducted by H3 Biomedicine's partner, Eisai.

Markus Warmuth, president and chief exe